As depicted in Figure 3C,D, quantitative assessment of CDK4 and Cyclin D1 expression revealed a dose-dependent decrease in AML cells (HL-60 and U937) relative to the control group. This evidence concerns the gene CDK4 and acute myeloid leukemia.